Windward Investments

Windward Bio is a clinical-stage biotechnology company focused on developing next-generation therapies for patients with advanced immunological and respiratory diseases. Launched in early 2025 with a $200 million Series A financing, the company is advancing a pipeline of long-acting biologics, led by WIN378, a monoclonal antibody targeting TSLP for severe asthma and COPD. Windward Bio is also developing WIN027, a bispecific antibody targeting both TSLP and IL-13, designed to provide superior efficacy and less frequent dosing compared to existing treatments. The company is led by a team of experienced biopharmaceutical executives and is backed by prominent investors including Novo Holdings and RTW Investments.